The recent unanimous decision by the US Supreme Court in Cunningham v. Cornell University marks a significant shift in the litigation landscape for fiduciaries and plan sponsors under the Employee Retirement Income Security Act (ERISA). The ruling affects all ERISA-governed plans, impacting the procedural obligations of fiduciaries regarding third-party transactions.
One of the central implications of the Supreme Court’s decision is the alteration of the pleading standards for prohibited transaction claims under Section 406(a)(1)(C). Plaintiffs are now no longer required to affirmatively plead the inapplicability of statutory exemptions under ERISA Section 408(b)(2)(A). Instead, this responsibility falls onto the fiduciaries, who must prove that the exemptions apply. As a result, transactions involving a “party in interest,” a definition broad enough to include regular relationships with service providers like recordkeepers and investment managers, can now survive early dismissal simply if challenged, regardless of merit. More details about this shift can be found on Bloomberg Law.
Justice Samuel Alito highlighted this broadened interpretation as potentially lowering the pleading threshold, a shift that may facilitate the advance of claims based solely on standard fiduciary practices. Since most ERISA plans involve such third-party relationships, nearly all could potentially become the subject of litigation under the revised framework.
Noteworthy is the Supreme Court’s endorsement of Federal Rule of Civil Procedure 7(a)(7), which could play a novel role in ERISA litigation. This rule requires plaintiffs to respond to specific affirmative defenses, forcing an early engagement with the defenses posed by fiduciaries. Traditionally, this procedural device is more common in qualified immunity cases. Its introduction into ERISA cases may help filter out meritless claims, although it might take years for courts and litigants to adapt fully to this change.
The Supreme Court also reinforced the importance of Article III standing, reminding that plaintiffs must plausibly allege personal harm to sustain a lawsuit, even in cases of prohibited transactions. This reinforcement may lead fiduciaries to more aggressively challenge standing, particularly where purported injuries are not explicitly connected to the transactions in question.
For fiduciaries, the emphasis on procedural safeguards, including Article III standing, judicious use of discovery management, and potential use of Rule 11 and ERISA’s fee-shifting provisions, offers tools to combat frivolous claims. However, these tools have historically been underutilized in ERISA litigation and may only deter plainly unfounded cases.
As plaintiffs now have an easier path past motion-to-dismiss stages, more claims are expected, including those challenging routine plan arrangements. This environment necessitates that fiduciaries and their legal counsel adopt proactive litigation strategies. These include asserting affirmative defenses, challenging standing where applicable, leveraging Rule 7(a)(7) replies, and advocating for phased discovery.
In this new litigious environment, fiduciaries are advised to strengthen their compliance and governance practices. Regular benchmarking, transparent fee processes, and documented vendor selection are crucial in mitigating litigation risks and demonstrating adherence to ERISA standards. For further examination of the case and implications, refer to Bloomberg Law.